Latest News & Updates
Breaking News
14 hours ago
Simantini Singh Deo
Other trending news you may like to read
AmMax Bio Licenses Lonza's SYNtecan Platform to Advance AML Candidate AMB-104 Toward 2027 IND
AmMax Bio licenses Lonza's SYNtecan ADC platform for AML candidate AMB-104, targeting a 2027 IND filing.
Simantini Singh Deo
GSK Acquires Nuvalent in $10.6 Billion Deal for Late-Stage Lung Cancer Pipeline
GSK's $10.6B Nuvalent acquisition adds ROS1/ALK lung cancer candidates, triggering immediate CMC and GMP integration obligations.
Simantini Singh Deo
FDA Launches Compounding Quality Center of Excellence Discussion Series for Outsourcing Facilities
FDA's Compounding Quality Center of Excellence opens two discussion series and a cross-sector group to help outsourcing facilities benchmark cGMP practices.
Simantini Singh Deo
Cellectis Gains FDA RMAT Designation for Lasme-cel in Pivotal Allogeneic CAR-T Program for r/r B-ALL
FDA grants RMAT designation to Cellectis's lasme-cel, accelerating the regulatory path for the first allogeneic CAR-T in a pivotal r/r B-ALL trial.
Simantini Singh Deo
